Atrial fibrillation: Rate control versus maintenance of sinus rhythm

Current Opinion in Cardiology

Volumn 16, Issue 1, 2001, Pages 46-53

  Donahue, Timothy P ^a   Conti, Jamie Beth ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b Box 100277 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DOFETILIDE; FLECAINIDE; IBUTILIDE; PLACEBO; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL;

ANTICOAGULANT THERAPY; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATION; DRUG INDUCED DISEASE; EXERCISE; FOLLOW UP; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SINUS RHYTHM; THROMBOEMBOLISM; TORSADE DES POINTES; TREATMENT OUTCOME;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ELECTRIC COUNTERSHOCK; HEART CONDUCTION SYSTEM; HEMODYNAMIC PROCESSES; HUMANS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 0035175734     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200101000-00007     Document Type: Review

References (59)

1. Detailed diagnoses and procedures for patients discharged from short-stay hospitals: United States 1984
2. Detailed diagnoses and procedures for patients discharged from short-stay hospitals. United States 1994
3. Cost-effective management of acute atrial fibrillation: Role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy
4. Therapy of atrial fibrillation: Rhythm control versus rate control
5. Cost-effective strategies in the acute management of atrial fibrillation
6. Investigators: Management of atrial fibrillation: The need for AFFIRMative action
7. Rhythm management in atrial fibrillation-with a primary emphasis on pharmacological therapy: Part 2
8. Duration of atrial fibrillation and imminence of stroke: The Framingham Study
9. Prevalence of embolic events after cardioversion of atrial fibrillation. Current and evolving strategies
10. The efficacy of anticoagulant therapy in preventing embolism related to D C. electrical conversion of atrial fibrillation
11. Transient atrial dysfunction after conversion of chronic atrial fibrillation to sinus rhythm
12. Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation
13. Mechanical dysfunction of the left atrium and the left atrial appendage following cardioversion of atrial fibrillation and its relation to total electrical energy used for cardioversion
14. Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: Characterization by simultaneous transesophageal echocardiography
15. Left atrial chamber and appendage function after internal atrial defibrillation: A prospective and serial transesophageal echocardiographic study
16. Effect of an irregular ventricular rhythm on cardiac output
17. Functional capacity before and after cardioversion of atrial fibrillation: A controlled study
18. Long-term effect of cardioversion on peak oxygen consumption in chronic atrial fibrillation: A 2-year follow up
19. The effect of cardioversion on maximal exercise capacity in patients with chronic atrial fibrillation
20. Tachycardia-induced cardiomyopathy: A reversible form of left ventricular dysfunction
21. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy
22. Impaired left atrial mechanical function after cardioversion: Relation to the duration of atrial fibrillation
23. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials
24. Proarrhythmic effects of flecainide. Experimental evidence for increased susceptibility to reentrant arrhythmias
25. Newer developments in the management of atrial fibrillation
26. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation
27. Blood quinidine concentrations as a guide in the treatment of cardiac arrhythmias
28. Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm
29. Flecainide versus amiodarone for recent onset atrial fibrillation
30. Prospective comparison of flecainide versus sotalol for immediate conversion of atrial fibrillation
31. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: A dose response study
32. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation
33. Superiority of ibutilide (a new class III agent) over d,l-sotalol in converting atrial flutter and atrial fibrillation
34. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainimide in patients with atrial flutter or fibrillation
35. Oral dofetilide for conversion of patients with chronic atrial fibrillation or atrial flutter to normal sinus rhythm: A multicenter study
36. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation
37. 3d: Evolving strategies for the management of atrial fibrillation. The role of amiodarone
38. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium
39. Amiodarone for refractory atrial fibrillation
40. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy
41. Effectiveness of amiodarone and electrical cardioversion for chronic rheumatic atrial fibrillation after mitral valve surgery
42. Dofetilide in the treatment of atrial fibrillation in patients with impaired left ventricular function
43. Comparison of alternating current with direct current electroshock across the closed chest
44. Management of atrial fibrillation
45. Factors determining success and energy requirements for cardioversion of atrial fibrillation
46. Antithrombotic treatment in atrial fibrillation
47. Design of a clinical trial for the assessment of cardioversion using transesophageal echocardiography
48. Low energy intracardiac cardioversion after failed conventional external cardioversion of atrial fibrillation
49. Atrial fibrillation: Nonpharmacologic approaches
50. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: Beneficial effect of an added beta adrenergic blocking agent
51. Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation: Impact of treatment in paroxysmal and established atrial fibrillation
52. The 1998 NASPE Prospective Catheter Ablation Registry
53. Correlation of symptoms with occurrence of paroxysmal supraventricular tachycardia or atrial fibrillation: A transtelephonic monitoring study
54. Mortality in an insured population with atrial fibrillation
55. Impact of atrial fibrillation on the risk of death. The Framingham study
56. Is conversion of atrial fibrillation the ultimate long-term goal?
57. Drug choices in the treatment of atrial fibrillation
58. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) study